Celgene Corp (CELG) - Financial and Strategic SWOT Analysis Review

Date: March 8, 2017
Pages: 68
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: CB9378AE000EN
Leaflet:

Download PDF Leaflet

Celgene Corp (CELG) - Financial and Strategic SWOT Analysis Review
Celgene Corp (CELG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Celgene Corp (Celgene) is an integrated global biopharmaceutical company that carries out the research, development, manufacture and marketing of novel therapies to treat cancer and immune-inflammatory related diseases through gene and protein regulation. Its product portfolio includes Vidaza (azacitidine) for the treatment of myelodysplastic syndromes (MDS); Revlimid (lenalidomide), Pomalyst (pomalidomide) and Thalomid (thalidomide) for the treatment of multiple myeloma; Abraxane (paclitaxel albumin-bound particles for injectable suspension) for various types of cancer; Otezla (apremilast) for psoriatic arthritis; and Istodax (romidepsin) for cutaneous T-cell lymphoma (CTCL) and eripheral T-cell lymphoma (PTCL). The company also has several products in various stages of development for the treatment of hematological and solid tumor cancers. It has manufacturing facilities in Boudry and Zofingen in Switzerland; and Arizona, the US. Celgene is headquartered in Summit, New Jersey, the US.

Celgene Corp Key Recent Developments

Feb 23, 2017: Celgene Announces Retirement of President and Chief Operating Officer, Jacqualyn Fouse, Ph.D. and Promotion of Scott Smith to President and Chief Operating Officer
Jan 26, 2017: Celgene Reports Fourth Quarter and Full-Year 2016 Operating and Financial Results
Jan 12, 2017: Celgene Increases Adoption of Medidata Clinical Cloud, Gaining Further Value from Implementation of Medidata's Strategic Monitoring and Data Analytics Solutions
Jan 09, 2017: Celgene Announces Preliminary 2016 Unaudited Results And 2017 Financial Guidance
Dec 03, 2016: Celgene, Dana-Farber Cancer Institute and University of Arkansas for Medical Sciences Establish the Myeloma Genome Project

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

Celgene Corp - Key Facts
Celgene Corp - Key Employees
Celgene Corp - Key Employee Biographies
Celgene Corp - Major Products and Services
Celgene Corp - Pharmaceutical Pipeline Products Data
Celgene Corp, Pipeline Products by Therapy Area
Celgene Corp, Pipeline Products by Development Phase
Celgene Corp - History
Celgene Corp - Company Statement
Celgene Corp - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Celgene Corp - Business Description
Celgene Corp - Corporate Strategy
Celgene Corp - SWOT Analysis
SWOT Analysis - Overview
Celgene Corp - Strengths
Celgene Corp - Weaknesses
Celgene Corp - Opportunities
Celgene Corp - Threats
Celgene Corp - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Celgene Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Celgene Corp, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Celgene Corp, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Feb 23, 2017: Celgene Announces Retirement of President and Chief Operating Officer, Jacqualyn Fouse, Ph.D. and Promotion of Scott Smith to President and Chief Operating Officer
Jan 26, 2017: Celgene Reports Fourth Quarter and Full-Year 2016 Operating and Financial Results
Jan 12, 2017: Celgene Increases Adoption of Medidata Clinical Cloud, Gaining Further Value from Implementation of Medidata's Strategic Monitoring and Data Analytics Solutions
Jan 09, 2017: Celgene Announces Preliminary 2016 Unaudited Results And 2017 Financial Guidance
Dec 03, 2016: Celgene, Dana-Farber Cancer Institute and University of Arkansas for Medical Sciences Establish the Myeloma Genome Project
Nov 22, 2016: Nearly 350 Abstracts Evaluating Celgene Therapies to Be Presented at American Society of Hematology Annual Meeting
Nov 01, 2016: Celgene and IBM Watson Health Forge Collaboration Designed to Transform Patient Safety Monitoring
Oct 27, 2016: Celgene Reports Third Quarter 2016 Operating and Financial Results
Oct 18, 2016: The Leukemia & Lymphoma Society Launches Groundbreaking Precision Medicine Approach to Treat Acute Myeloid Leukemia, One of the Deadliest Blood Cancers
Oct 18, 2016: Celgene and Sage Bionetworks Announce Technology Collaboration to Develop Observational Study Using the Apple ResearchKit Framework

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Celgene Corp, Key Facts
Celgene Corp, Key Employees
Celgene Corp, Key Employee Biographies
Celgene Corp, Major Products and Services
Celgene Corp, Number of Pipeline Products by Therapy Area
Celgene Corp, Number of Pipeline Products by Development Stage
Celgene Corp, History
Celgene Corp, Other Locations
Celgene Corp, Subsidiaries
Celgene Corp, Key Competitors
Celgene Corp, Ratios based on current share price
Celgene Corp, Annual Ratios
Celgene Corp (Cont...1), Annual Ratios
Celgene Corp, Interim Ratios
Celgene Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Celgene Corp, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Celgene Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Celgene Corp, Pipeline Products by Therapy Area
Celgene Corp, Pipeline Products by Development Phase
Celgene Corp, Performance Chart (2012 - 2016)
Celgene Corp, Ratio Charts
Celgene Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Celgene Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

COMPANIES MENTIONED

Takeda Pharmaceutical Company Ltd
Sanofi
Novartis AG
Merck & Co Inc
Johnson & Johnson
Genentech Inc
Eli Lilly and Company
Eisai Co Ltd
Bristol-Myers Squibb Company
Biogen Inc
AstraZeneca Plc
Amgen Inc
Abbott Laboratories
Skip to top


Ask Your Question

Celgene Corp (CELG) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: